Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eastern Virginia Medical School

Latest From Eastern Virginia Medical School

The Search for Prostate-Specific Answers

Diseases of the prostate constitute the second most prevalent type of chronic disease in the male population in the US. The recent report "US Markets for Diagnostic and Therapeutic Prostate Disease/Disorder Management Products," a report published in August 2007 by the Medtech Insight division of Windhover Information, details the state-of-the industry for companies working in benign prostatic hyperplasia, prostate cancer, and prostatitis. A brief excerpt on biomarkers for prostate cancer appears here.

BioPharmaceutical Medical Device

Recent Tech Transfer Deals (5/06)

Each month, Start-Up presents a survey of technology transfer deals-licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

Light BioScience LLC

Light BioScience LLC is a pioneer in the use of light-emitting diodes for nonablative skin resurfacing and rejuvenation. Its GentleWaves LED Photomodulation system uses very specific pulses of near-infrared light to boost collagen production. The device has initial FDA clearance for treating periorbital wrinkles, but the company is amassing clinical data about its effectiveness in several other aesthetic, and some non-aesthetic, indications.

Medical Device

From Generics to Brands: Barr's Women's Health Franchise

Barr remains committed to building a leading women's health franchise even as it encounters setbacks, big and small, most recently in the FDA's rejection of its application for over-the-counter status for its emergency contraceptive, Plan B. Even more problematic is the ongoing turmoil in the hormone replacement therapy markets. It recently launched its first proprietary product, indicating its skill in getting an NDA drug through the FDA and newly acquired marketing savvy.

BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Academic and Research Institutions